Clinical Cell Culture Announce Quarterly Update
Clinical Cell Culture Ltd (ASX: CCE) today released its quarterly report, Appendix 4C, for the quarter ending 30 June 2007.
Companies in the News
Biotech
Australian Biotech Solagran Registers New Pharmaceutical in Russia
The Directors of Solagran Limited (ASX: SLA) are pleased to announce that the Company has received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both the substance Bioeffective® R and the medicine Ropren has been finalised.
Life Therapeutics to Deliver on Vertical Integration Strategy Through Partnership with Leading Fractionator
Life Therapeutics (ASX: LFE) today provided details of an agreement (the "Agreement") with Kedrion S.p.A ("Kedrion"), a leading European speciality pharmaceutical company and Italy's largest fractionator, that will enable the company to deliver on its strategy to become a vertically integrated operator. Under the terms of the Agreement, Life Therapeutics will take up a 5.5% equity stake in Kedrion and will divest assets from its Life Sera business into a new joint venture company with Kedrion ("Newco").
Solagran Upgrade to Bioeffective(r) R Manufacturing Capacity
The Directors of Solagran are pleased to announce a number of important decisions taken in relation to upgrading the company's Bioeffective(r) R manufacturing capacity.
Solagran; Feedback from Gastro-2007 Conference in St Petersburg
The Directors of Solagran Limited (ASX: SLA) are pleased to release the attached letter which has been received from the organising committee of the Gastro-2007 Conference in St Petersburg.
Life Therapeutics Update on Status of Heads of Agreement with European Fractionator
On 19 March 2007 Life Therapeutics (ASX: LFE) (PNK: LFEFY) announced that it had entered into a non-binding Heads of Agreement with a European fractionator in relation to a proposed transaction. At that time, the company granted to the European fractionator exclusive negotiation rights up until 1 June 2007.
Cordlife To Rationalise Technology And Product Development Activities, To Further Focus On Cord Blood Banking Business
Leading Cord Blood Banking company Cordlife Ltd (ASX: CBB) today announced that it plans to introduce new shareholders to its wholly owned Cytomatrix Group, which holds its patented cell expansion (Transtem) and T-cell production (Regenimmune) technologies.
◂Previous Page
Biotech Next Page▸
Banking & Finance
- VIDEO: Lion Selection Group Ltd (ASX:LSX) CEO Hedley Widdup and Sean Russo Talk at the Australian Gold Conference 2024
- VIDEO: The Australian Gold Conference 2024 - Education Evening with Expert Panel
- Lithium Universe Ltd (ASX:LU7) Finalises Frankfurt and US OTC Listing
- ISX Financial Reports Strong Q2 2024 Results, Highlighting Robust Growth and Innovation
- NSX Limited (ASX:NSX) Company Update
- ASIC vs iSignthis Ltd and Nickolas John Karantzis
Oil Gas & Energy
- TMK Energy Limited (ASX:TMK) LF-07 Intersects 54 Metres of net Coal
- Central Petroleum Limited (ASX:CTP) Live Online Investor Presentation
- State Gas Limited (ASX:GAS) Quarterly Activities Report
- Beetaloo Energy Australia Limited (ASX:BTL) Quarterly Activities Report - 30 June
- Basin Energy Ltd (ASX:BSN) Quarterly Activities Report
- Central Petroleum Limited (ASX:CTP) Share Buy-Back
Life Sciences
- Ellis Martin Report: Redefining Cancer Treatment - RenovoRx, Inc. (NASDAQ:RNXT) CEO Shaun Bagai on Targeted Pancreatic Therapy
- BPH Energy Limited (ASX:BPH) Quarterly Activities Report
- Proteomics International Laboratories Ltd (ASX:PIQ) Quarterly Activities/Appendix 4C Cash Flow Report
- Proteomics International Laboratories Ltd (ASX:PIQ) Next-Gen PromarkerD Test Performance Results Published
- Proteomics International Laboratories Ltd (ASX:PIQ) OxiDx Test Detects Muscle Damage in Thoroughbred Racehorses
- Proteomics International Laboratories Ltd (ASX:PIQ) AMA Grants Reimbursement Code for Next-Gen PromarkerD Test
Social Media
